2024 Avoca Industry Report: ICH E6 (R3) Impact & Preparedness

For more than 20 years, Avoca has surveyed industry executives to gain an understanding of key trends affecting clinical development. This year’s research is focused on potential changes in regulatory guidance under ICH E6 (R3) to gain understanding of current awareness and perceived impacts – both positive and negative – among clinical trial stakeholders to navigate the path forward.

This report summarizes key findings to provide a multi-faceted view on the effects of upcoming guidance changes from the perspectives of sponsors, providers, and site personnel, addressing the preparations involved with the goal of fostering collaboration and successful implementation.

Access Report ››

Avoca, a WCG company, is dedicated to improving the clinical trial execution process with industry-leading approaches and technology. WCG’s suite of Benchmarking, Analytics, and Consulting solutions help elevate clinical trial quality, compliance, and efficiency with industry expertise and data intelligence to guide better decisions.
Learn more ››